Aybuke Alisan

Aybuke Alisan

Auto-generated profile, based on publicly available information

Aybuke Alisan

Department of Pediatric Rheumatology, Faculty of Medicine, Cukurova University, Adana, Turkey

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2026 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
PEPuren Isik Eker
Puren Isik Eker
AAAybuke Alisan
Aybuke Alisan
PMPanayiotis Maghsoudlou
Panayiotis Maghsoudlou
SBSibel Balci
Sibel Balci
RERabia Miray Kisla Ekinci
Rabia Miray Kisla Ekinci
NDNihal Demircan
Nihal Demircan
To compare macular microvascular and microstructural exploratory imaging findings in patients with childhood-onset mevalonate kinase deficiency (MKD) and healthy controls, and to assess associations with disease activity. This cross-sectional case-control study included patients with childhood-onset, genetically confirmed MKD and healthy controls. Disease activity was assessed using the autoinflammatory disease activity index (AIDAI) score and C-reactive protein (CRP) levels. Choroidal images were obtained to measure subfoveal choroidal thickness (SFCT) and to calculate the total choroidal area (TCA), luminal area (LA), stromal area (SA), and the choroidal vascularity index (CVI). Macular optical coherence tomography (OCT) and optical coherence tomography-angiography (OCT-A) parameters were compared between groups, and associations with systemic disease activity were examined. The study included 17 patients with childhood-onset MKD and 30 healthy controls. The MKD group showed higher LA and CVI than in controls (p = 0.042 and p = 0.014, respectively), whereas TCA and SA were comparable between groups (p = 0.124 and p = 0.669, respectively). Mean central macular thickness was lower in the MKD group (p = 0.030), while SFCT was comparable between groups (p = 0.325). No significant differences were observed in macular microvascular parameters. Patients with childhood-onset MKD showed higher CVI, whereas macular microvascular parameters were comparable to those of controls. These findings may suggest subtle alterations in choroidal vascular composition, potentially related to the underlying inflammatory milieu; however, given that all patients were receiving canakinumab treatment, they should be interpreted cautiously as exploratory associations requiring confirmation in longitudinal studies.

14 October 2026 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
ZAZeynep Kucukakcali Arslan
Zeynep Kucukakcali Arslan
AAAybuke Alisan
Aybuke Alisan
YDYasargul Denli
Yasargul Denli
STSuhan Gunasti Topal
Suhan Gunasti Topal
RERabia Miray Kisla Ekinci
Rabia Miray Kisla Ekinci

27 October 2026 in Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
Verified
Journal Article
Closed access
AAAybuke Alisan
Aybuke Alisan
NANergis Akay
Nergis Akay
RERabia Miray Kisla Ekinci
Rabia Miray Kisla Ekinci
MYMehmet Yildiz
Mehmet Yildiz
SSSezgin Sahin
Sezgin Sahin
OKOzgur Kasapcopur
Ozgur Kasapcopur
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease exhibiting clinical heterogeneity among affected individuals. In monogenic lupus, which results from single-gene mutations, there is an early onset, atypical and severe course, and usually a familial predisposition. One of the common causes of monogenic SLE is deficiencies in the early components of the classical pathway of the complement system. We present here a 9-year-old male with hereditary C1R deficiency, suffering from chronic discoid rash since the age of 18 months, who did not sufficiently respond to conventional treatment, including topical and systemic steroids, hydroxychloroquine, mycophenolate mofetil, intravenous immunoglobulin, and baricitinib. Subsequently, the skin findings improved after the initiation of anifrolumab, an anti-IFNAR antibody. To the best of our knowledge, this report represents the first successful treatment of monogenic lupus and C1R deficiency with anifrolumab in the literature.

28 July 2026 in Zeitschrift für Rheumatologie
Verified
Journal Article
Closed access
PDF file
AAAybuke Alisan
Aybuke Alisan
SBSeyda Besen
Seyda Besen
RERabia Miray Kisla Ekinci
Rabia Miray Kisla Ekinci
AUAysun Uguz
Aysun Uguz
UCUmmuhan Cay
Ummuhan Cay
IEIlknur Erol
Ilknur Erol

1 October 2026 in Rheumatology
Verified
Journal Article
Open access
NANergis Akay
Nergis Akay
SSSezgin Sahin
Sezgin Sahin
SUSila Atamyildiz Ucar
Sila Atamyildiz Ucar
AAAybuke Alisan
Aybuke Alisan
ETEray Tunce
Eray Tunce
OKOzgur Kasapcopur
Ozgur Kasapcopur
Objectives: With advances in genetic testing, monogenic lupus is increasingly recognized, yet disease-specific classification criteria are lacking. We compared all three classification criteria sets in the same monogenic lupus cohort and, for the first time, evaluated their performance across distinct genetic pathways. Methods: This national multicentre study included 88 genetically confirmed monogenic lupus patients from 22 paediatric rheumatology centres across Türkiye. Fulfilment of the AmericanCollege of Rheumatology (ACR)-1997, Systemic Lupus International Collaborating Clinics (SLICC)-2012 and European League Against Rheumatism (EULAR)/ACR-2019 criteria and pathway-based differences in classification performance were assessed. Results: Overall, 74% (n = 65) fulfilled ACR-1997, 70.5% (n = 62) SLICC-2012 and EULAR/ACR-2019 criteria, and 62.5% (n = 55) met all three, whereas 17% (n = 15) met none. Agreement was substantial (κ = 0.63–0.73), with no significant differences between criteria (P > 0.05). Classification performance differed significantly across genetic pathways (P < 0.05), with the highest fulfilment performances in complement deficiencies and the lowest in nucleic acid metabolism and type I interferon pathway defects. Most patients who did not fulfil any classification criteria had nucleic acid metabolism and clearance defects (13/15, 86.7%). Domain-level analyses showed that classification success was mainly driven by mucocutaneous, immunologic and renal domains. Complement and immune-regulation defects showed a more classical lupus phenotype, with most fulfilling all three criteria (78.6%, 22/28 and 77.8%, 14/18), whereas the proportion was lower in type I interferon pathway and nucleic acid metabolism and clearance defects (33.3%, 2/6 and 47.2%, 17/36). No classification criteria were superior within genetic pathways. Conclusion: One-third of genetically confirmed monogenic lupus patients remained unclassified, particularly those with interferon-related and nucleic acid metabolism defects, highlighting pathway-dependent limitations of current classification criteria.